Proteon Therapeutics, which is developing a treatment to reduce the failure rates of a dialysis-related procedure, raised $61 million by offering 6.1 million shares at $10, below the range of $12 to $14. Proteon Therapeutics plans to list on the NASDAQ under the symbol PRTO. Proteon Therapeutics initially filed confidentially on 6/25/2014. Stifel and JMP Securities acted as lead managers on the deal.
